SOX9 and pancreatic neoplasm: Our discovery that miR-485-3p targets SOX9 and SLC7A11 to inhibit stemness-like properties and gemcitabine resistance provides new insights into the regulation of hypoxia, CSCs, and chemoresistance in pancreatic cancer.